Bouchard Véronique J, Rouleau Michèle, Poirier Guy G
Health and Environment Unit, Faculty of Medicine, Laval University Medical Research Center, 2705 Boulevard Laurier, Ste-Foy, Québec, Canada G1V 4G2.
Exp Hematol. 2003 Jun;31(6):446-54. doi: 10.1016/s0301-472x(03)00083-3.
Poly(ADP-ribose) polymerase-1 (PARP-1) plays a primary role in the process of poly(ADP-ribosyl)ation. This posttranslational modification of nuclear proteins is activated in response to DNA damage. Having been studied for more than 30 years, PARP-1 is now known to be implicated in several crucial cellular processes: DNA replication, transcription, DNA repair, apoptosis, and genome stability. In this review, we focus on recent findings suggesting that PARP-1 participates in DNA damage signaling in cell death. Of clinical relevance is its role in cancer therapy, irradiation, and chemotherapy, all of which may cause DNA damage and overactivate PARP-1, resulting in inflammation caused by necrosis. Therefore, we will discuss how inhibition of PARP-1 may enhance the efficiency of cancer therapy.
聚(ADP-核糖)聚合酶-1(PARP-1)在聚(ADP-核糖基)化过程中起主要作用。这种核蛋白的翻译后修饰在DNA损伤时被激活。经过30多年的研究,现在已知PARP-1参与多种关键的细胞过程:DNA复制、转录、DNA修复、细胞凋亡和基因组稳定性。在这篇综述中,我们重点关注近期的研究发现,这些发现表明PARP-1参与细胞死亡中的DNA损伤信号传导。其在癌症治疗、放疗和化疗中的作用具有临床相关性,所有这些都可能导致DNA损伤并过度激活PARP-1,从而导致坏死引起的炎症。因此,我们将讨论抑制PARP-1如何提高癌症治疗的效率。